The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa

被引:30
作者
Anand, Kanchan [1 ]
Pallares, Irantzu [2 ]
Valnickova, Zuzana [3 ,4 ]
Christensen, Trine [3 ,4 ]
Vendrell, Josep [2 ]
Wendt, K. Ulrich [1 ]
Schreuder, Herman A. [1 ]
Enghild, Jan J. [3 ,4 ]
Aviles, Francesc X. [2 ]
机构
[1] Sanofi Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany
[2] Univ Autonoma Barcelona, Inst Biotecnol Biomed, E-08193 Barcelona, Spain
[3] Aarhus Univ, Dept Mol Biol, Ctr Insoluble Prot Struct inSPIN, DK-8000 Aarhus C, Denmark
[4] Aarhus Univ, Dept Mol Biol, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus C, Denmark
关键词
D O I
10.1074/jbc.M804003200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mature thrombin-activable fibrinolysis inhibitor (TAFIa) is a highly unstable metallocarboxypeptidase that stabilizes blood clots by clipping C-terminal lysine residues from partially degraded fibrin. In accordance with its in vitro antifibrinolytic activity, animal studies have reported that inhibition of mature TAFI aids in the prevention of thrombosis. The level of TAFI activity is stringently regulated through (i) controlled proteolytic truncation of the zymogen (TAFI), generating the mature enzyme, TAFIa, and (ii) the short half-life of TAFIa. TAFI itself exhibits an intrinsic enzymatic activity, which is likely required to provide a baseline level of antifibrinolytic activity. The novel crystal structure presented here reveals that the active site of TAFI is accessible, providing the structural explanation for the its intrinsic activity. It also supports the notion that an "instability region" exists, in agreement with site-directed mutagenesis studies. Sulfate ions, bound to this region, point toward a potential heparin-binding site and could explain how heparin stabilizes TAFIa.
引用
收藏
页码:29416 / 29423
页数:8
相关论文
共 34 条
[1]   Metallocarboxypeptidases: Emerging drug targets in biomedicine [J].
Arolas, Joan L. ;
Vendrell, Josep ;
Aviles, Francesc X. ;
Fricker, Lloyd D. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (04) :349-366
[2]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[3]   Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties [J].
Boffa, MB ;
Wang, W ;
Bajzar, L ;
Nesheim, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) :2127-2135
[4]   Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor [J].
Boffa, MB ;
Bell, R ;
Stevens, WK ;
Nesheim, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) :12868-12878
[5]   Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) [J].
Bouma, BN ;
Marx, PF ;
Mosnier, LO ;
Meijers, JCM .
THROMBOSIS RESEARCH, 2001, 101 (05) :329-354
[6]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[7]   Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis [J].
Campbell, W ;
Okada, N ;
Okada, H .
IMMUNOLOGICAL REVIEWS, 2001, 180 :162-167
[8]   Comparative evaluation of stable TAFIa variants:: importance of α-helix 9 and β-sheet 11 for TAFIa (in)stability [J].
Ceresa, E. ;
De Maeyer, M. ;
Jonckheer, A. ;
Peeters, M. ;
Engelborghs, Y. ;
Declerck, P. J. ;
Gils, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (10) :2105-2112
[9]   Generation of a stable activated thrombin activable fibrinolysis inhibitor variant [J].
Ceresa, Erik ;
de Borne, Kirsten Van ;
Peeters, Miet ;
Lijnen, Henri Roger ;
Declerck, Paul J. ;
Gils, Ann .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (23) :15878-15883
[10]  
COLL M, 1991, EMBO J, V10, P1